Stock Quotes & Company News | Reuters.com
Edition:
United States

People: Vexim SA (ALVXM.PA)

ALVXM.PA on Paris Stock Exchange

8.10EUR
11:24am EDT
Change (% chg)

€0.07 (+0.87%)
Prev Close
€8.03
Open
€8.06
Day's High
€8.29
Day's Low
€8.02
Volume
3,246
Avg. Vol
7,683
52-wk High
€12.12
52-wk Low
€6.99

Pouletty, Philippe 

Dr. Philippe Pouletty is Director - Representative of Truffle Capital at Vexim SA. A Doctor of Medicine, Immunologist, former intern of the Paris Hospitals, laureate from Pasteur Institute (immunology) and postdoctoral fellow at Stanford University, he is the inventor of 29 patents. Dr. Pouletty is the Founder and Managing Director of Truffle Capital and was the President of France Biotech, the French association of biotechnology companies, and former Vice President of EuropaBio, the European Federation of Biotechnology. He was also the founder of three biotechnology companies in Europe and the United States and is a member of the board of several biotechnology and medical device companies in Europe and North America, including BMD, Carmat, Deinove, Innate Pharma, ITS, Neovacs, Pharnext, PlasmaPrime, Splicos, Symetis, Theraclion and Wittycell. Dr. Pouletty also took part in several governmental initiatives in France, including the 1999 act to for simplifying company law (SAS), the Plan Biotech 2002 for launching and developing biotechnology and the Young Innovative Enterprise status which have tax exemptions to technology companies. He obtained a Doctorate of Medicine degree from Universite Paris VI Pierre et Marie Curie. He also received a degree in Immunology from Institut Pasteur, Paris and graduated from the Stanford University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --